CathVision, a Copenhagen, Denmark-based medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, completed an investment round of a total €13M.
Both existing and new investors participated in the round. Vaekstfonden invested in Cathvision already in 2017 and participated in the new round as well.
The proceeds allow the company to begin multi-center clinical studies and complete its FDA approval process for the CathVision Cube system and associated software algorithms.
Led by CEO Mads Emil Matthiesen, CathVision is developing and selling medical devices to treat cardiac arrhythmias. The solutions are centered on an innovative electrophysiology (EP) system to provide exceptional EP signals for identification and characterization of arrhythmias. The company also has a US business office in Minnesota USA.